Format

Send to

Choose Destination
Drug Dev Res. 2015 Dec;76(8):419-27. doi: 10.1002/ddr.21285. Epub 2015 Oct 20.

Safety of Anti-TNF Therapies in Immune-Mediated Inflammatory Diseases: Focus on Infections and Malignancy.

Author information

1
Instituto de Ciências Biomédicas Abel Salazar, Centro Hospitalar do Porto, Portugal.
2
Department of Gastroenterology, Centro Hospitalar do Porto, Portugal.
3
Clinical Immunology Unit, Centro Hospitalar do Porto, Portugal.
4
Department of Dermatology, Centro Hospitalar do Porto, Portugal.

Abstract

Preclinical Research The efficacy of anti-TNF agents in the treatment of multiple immune-mediated inflammatory diseases (IMIDs) has increased their daily use. However, concerns remain regarding their long-term safety profile. Using a literature-based review of the infectious and malignant complications of anti-TNF biologics in IMIDs including psoriasis, Rheumatoid Arthritis, and inflammatory bowel disease, this review presents current evidence relative to the safety of anti-TNF agents in the context infections and malignancy in adults with IMIDs. Treatment with anti-TNF biologics is an effective treatment option with known risks that can be mitigated by appreciating the safety aspects and via a thorough screening and continuous monitoring of the patient.

KEYWORDS:

anti-TNFa therapies; immune-mediated inflammatory diseases; infection; inflammatory bowel disease; malignancy; psoriasis; rheumatoid arthritis; safety

PMID:
26482111
DOI:
10.1002/ddr.21285
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center